Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
16.88
+0.13 (0.75%)
At close: Sep 11, 2026, 4:00 PM EDT
16.85
-0.02 (-0.15%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Rallybio Employees
Rallybio had 7 employees as of June 30, 2026. The number of employees decreased by 13 or -65.00% compared to the same quarter last year.
Employees
7
Change
-13
Growth
-65.00%
Revenue / Employee
$92,286
Profits / Employee
$6,507,286
Market Cap
89.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 7 | -13 | -65.00% |
| Mar 31, 2026 | 9 | -15 | -62.50% |
| Dec 31, 2025 | 14 | -11 | -44.00% |
| Sep 30, 2025 | 15 | -10 | -40.00% |
| Jun 30, 2025 | 20 | -5 | -20.00% |
| Mar 31, 2025 | 24 | -6 | -20.00% |
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Sep 30, 2024 | 25 | -19 | -43.18% |
| Jun 30, 2024 | 25 | -20 | -44.44% |
| Mar 31, 2024 | 30 | -13 | -30.23% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Sep 30, 2023 | 44 | 0 | - |
| Jun 30, 2023 | 45 | 0 | - |
| Mar 31, 2023 | 43 | 3 | 7.50% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Sep 30, 2022 | 44 | 13 | 41.94% |
| Jun 30, 2022 | 45 | 17 | 60.71% |
| Mar 31, 2022 | 40 | 12 | 42.86% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Verrica Pharmaceuticals | 76 |
| ImmuCell | 73 |
| Cardiff Oncology | 31 |
| iBio, Inc. | 23 |
| MediciNova | 6 |
RLYB News
- 5 weeks ago - Rallybio Quarterly report: Q2 2026 - Filings
- 3 months ago - Rallybio to acquire Avenzo Therapeutics through merger transaction - TheFly
- 3 months ago - Rallybio Transcript: M&A announcement - Transcripts
- 3 months ago - Rallybio Press release: M&A announcement - Filings
- 3 months ago - Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - Business Wire
- 4 months ago - Rallybio Quarterly report: Q1 2026 - Filings
- 5 months ago - Rallybio Annual report: Q4 2025 - Filings
- 6 months ago - Rallybio, Candid Therapeutics announce merger agreement - TheFly